SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In
 
We’re going down soon, to move to a new Data Center today.  We’ll be up ASAP.  Sorry.

Allogene Therapeutics, Inc. – ‘10-K’ for 12/31/22 – ‘EX-4.3’

On:  Tuesday, 2/28/23, at 4:12pm ET   ·   For:  12/31/22   ·   Accession #:  1737287-23-18   ·   File #:  1-38693

Previous ‘10-K’:  ‘10-K’ on 2/23/22 for 12/31/21   ·   Next:  ‘10-K/A’ on 3/14/24 for 12/31/22   ·   Latest:  ‘10-K’ on 3/14/24 for 12/31/23   ·   26 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/28/23  Allogene Therapeutics, Inc.       10-K       12/31/22   82:11M

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.42M 
 2: EX-4.3      Instrument Defining the Rights of Security Holders  HTML     39K 
 3: EX-10.13    Material Contract                                   HTML    148K 
 4: EX-23.1     Consent of Expert or Counsel                        HTML     24K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     25K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     25K 
14: R1          Cover Page                                          HTML     86K 
15: R2          Audit Information                                   HTML     28K 
16: R3          Consolidated Balance Sheets                         HTML    121K 
17: R4          Consolidated Balance Sheets (Parenthetical)         HTML     41K 
18: R5          Consolidated Statements of Operations and           HTML     87K 
                Comprehensive Loss                                               
19: R6          Consolidated Statements of Stockholders? Equity     HTML     89K 
20: R7          Consolidated Statements of Convertible Preferred    HTML     26K 
                Stock and Stockholders? Equity (Deficit)                         
                (Parenthetical)                                                  
21: R8          Consolidated Statements of Cash Flows               HTML    117K 
22: R9          Description of Business and Summary of Significant  HTML     65K 
                Accounting Policies                                              
23: R10         Recent Accounting Guidance                          HTML     36K 
24: R11         Fair Value Measurements                             HTML     61K 
25: R12         Investments                                         HTML     75K 
26: R13         Balance Sheet Components                            HTML     45K 
27: R14         License and Collaboration Agreements                HTML     63K 
28: R15         Commitments and Contingencies                       HTML     58K 
29: R16         Equity Method Investment                            HTML     28K 
30: R17         Stockholders' Equity                                HTML     31K 
31: R18         Stock-Based Compensation                            HTML     97K 
32: R19         Related Party Transactions                          HTML     33K 
33: R20         401(k) Plan                                         HTML     28K 
34: R21         Income Taxes                                        HTML     94K 
35: R22         Net Loss and Net Loss Per Share                     HTML     44K 
36: R23         Subsequent Events                                   HTML     25K 
37: R24         Description of Business and Summary of Significant  HTML    109K 
                Accounting Policies (Policies)                                   
38: R25         Description of Business and Summary of Significant  HTML     27K 
                Accounting Policies (Tables)                                     
39: R26         Fair Value Measurements (Tables)                    HTML     57K 
40: R27         Investment (Tables)                                 HTML     72K 
41: R28         Balance Sheet Components (Tables)                   HTML     46K 
42: R29         Commitments and Contingencies (Tables)              HTML     50K 
43: R30         Stock-Based Compensation (Tables)                   HTML     86K 
44: R31         Income Taxes (Tables)                               HTML     94K 
45: R32         Net Loss and Net Loss Per Share (Tables)            HTML     46K 
46: R33         Description of Business and Summary of Significant  HTML     70K 
                Accounting Policies - Additional Information                     
                (Details)                                                        
47: R34         Description of Business and Summary of Significant  HTML     35K 
                Accounting Policies - Schedule of Estimated Life                 
                of Assets (Details)                                              
48: R35         Fair Value Measurements - Additional Information    HTML     31K 
                (Detail)                                                         
49: R36         Fair Value Measurements - Financial Assets          HTML     62K 
                Measured at Fair Value on Recurring Basis (Detail)               
50: R37         Investments - Summary of Cash Equivalents,          HTML     58K 
                Restricted Cash and Investments, Classified as                   
                Available-for-Sale Securities (Details)                          
51: R38         Investments - Schedule of Fair Values of Available  HTML     35K 
                For Sale Debt Investments by Contractual Maturity                
                (Detail)                                                         
52: R39         Investment - Additional Information (Details)       HTML     33K 
53: R40         Balance Sheet Components - Schedule of Property     HTML     42K 
                and Equipment, Net (Details)                                     
54: R41         Balance Sheet Components - Additional Information   HTML     27K 
                (Details)                                                        
55: R42         Balance Sheet Components - Schedule of Accrued      HTML     34K 
                Liabilities (Details)                                            
56: R43         License and Collaboration Agreements (Details)      HTML    187K 
57: R44         Commitments and Contingencies - Additional          HTML     74K 
                Information (Details)                                            
58: R45         Commitments and Contingencies - Lease Liabilities   HTML     31K 
                (Details)                                                        
59: R46         Commitments and Contingencies - Lease Costs         HTML     30K 
                (Details)                                                        
60: R47         Commitments and Contingencies - Summary of          HTML     40K 
                Undiscounted Future Non-Cancellable Lease Payments               
                Under Operating Leases (Details)                                 
61: R48         Equity Method Investment (Details)                  HTML     49K 
62: R49         Stockholders' Equity (Details)                      HTML     38K 
63: R50         Stock-Based Compensation - Additional Information   HTML    141K 
                (Details)                                                        
64: R51         Stock-Based Compensation - Stock Option Activity    HTML     85K 
                (Details)                                                        
65: R52         Stock-Based Compensation - Schedule of Share-based  HTML     46K 
                Payment Award, Stock Options, Valuation                          
                Assumptions (Details)                                            
66: R53         Stock-Based Compensation - Summary of Restricted    HTML     64K 
                Stock Activity (Details)                                         
67: R54         Stock-Based Compensation - Schedule of Share-based  HTML     43K 
                Payment Award, Employee Stock Purchase Plan,                     
                Valuation Assumptions (Details)                                  
68: R55         Stock-Based Compensation - Schedule of Stock-Based  HTML     30K 
                Compensation Expense (Details)                                   
69: R56         Related Party Transactions (Details)                HTML     96K 
70: R57         401(k) Plan (Details)                               HTML     26K 
71: R58         Income Taxes - Schedule of Income Tax               HTML     41K 
                Reconciliation (Details)                                         
72: R59         Income Taxes - Schedule of Deferred Tax Assets and  HTML     63K 
                Liabilities (Details)                                            
73: R60         Income Taxes - Additional Information (Details)     HTML     32K 
74: R61         Income Taxes - Summary of Operating Loss            HTML     39K 
                Carryforwards and Tax Credits (Details)                          
75: R62         Income Taxes - Schedule of Reconciliation of        HTML     35K 
                Unrecognized Tax Benefits (Details)                              
76: R63         Net Loss and Net Loss Per Share - Schedule of       HTML     55K 
                Earnings Per Share Basic and Diluted (Details)                   
77: R64         Net Loss and Net Loss Per Share - Schedule of       HTML     39K 
                Anti-dilutive Shares (Details)                                   
80: XML         IDEA XML File -- Filing Summary                      XML    147K 
78: XML         XBRL Instance -- allo-20221231_htm                   XML   2.13M 
79: EXCEL       IDEA Workbook of Financial Reports                  XLSX    172K 
10: EX-101.CAL  XBRL Calculations -- allo-20221231_cal               XML    181K 
11: EX-101.DEF  XBRL Definitions -- allo-20221231_def                XML    640K 
12: EX-101.LAB  XBRL Labels -- allo-20221231_lab                     XML   1.81M 
13: EX-101.PRE  XBRL Presentations -- allo-20221231_pre              XML   1.05M 
 9: EX-101.SCH  XBRL Schema -- allo-20221231                         XSD    194K 
81: JSON        XBRL Instance as JSON Data -- MetaLinks              445±   705K 
82: ZIP         XBRL Zipped Folder -- 0001737287-23-000018-xbrl      Zip   1.57M 


‘EX-4.3’   —   Instrument Defining the Rights of Security Holders


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

Exhibit 4.3
DESCRIPTION OF COMMON STOCK
General
The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refer to our amended and restated certificate of incorporation (the “Restated Certificate”) and amended and restated bylaws (the “Restated Bylaws), which are included as exhibits to our Annual Report on Form 10-K, and to the applicable provisions of Delaware law. Our authorized capital stock consists of 400,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. Our board of directors has the authority, without stockholder approval, except as required by the listing standards of The Nasdaq Stock Market LLC, to issue additional shares of our capital stock. In addition, our board of directors has the authority, without further action by our stockholders, to designate the rights, preferences, privileges, qualifications and restrictions of our preferred stock in one or more series.
Voting Rights
Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.
Dividends and Distributions
Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.
Liquidation, Dissolution or Winding Up
In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.
Other Rights and Preferences
Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.
Fully Paid and Nonassessable
All of our outstanding shares of common stock are fully paid and nonassessable.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC.
Stock Exchange Listing
1


Our common stock is listed on The Nasdaq Global Select Market under the symbol “ALLO.”
Anti-Takeover Provisions
Delaware Anti-Takeover Law
We are subject to Section 203 of the Delaware General Corporation Law (“DGCL”), which generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
on or subsequent to the consummation of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.
Section 203 of the DGCL defines a business combination to include:
any merger or consolidation involving the corporation and the interested stockholder;
any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;
subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder;
subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; and
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.
In general, Section 203 of the DGCL defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws Provisions
Provisions of the Restated Certificate and the Restated Bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, the Restated Certificate and the Restated Bylaws:
2


permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);
provide that the authorized number of directors may be changed only by resolution of the board of directors;
provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66 2/3% of the voting power of all of our then outstanding common stock;
provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
divide our board of directors into three classes;
require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;
provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder’s notice;
do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); and
provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.
The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66 2/3% of our then outstanding common stock.
The foregoing provisions may make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.
These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.
Choice of Forum
Our Restated Certificate and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the
3


State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors or officers or other employees arising out of or pursuant to any provision of the DGCL, our Restated Certificate or Restated Bylaws (including any right, obligation, or remedy thereunder); (iv) any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (v) any action asserting a claim against us or any of our directors or officers or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court’s having personal jurisdiction over the indispensable parties named as defendants. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. This choice of forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction.
Further, our Restated Certificate and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.
4

10 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/14/24  Allogene Therapeutics, Inc.       10-K       12/31/23   95:17M
 3/14/24  Allogene Therapeutics, Inc.       10-K/A     12/31/22   89:12M
 3/14/24  Allogene Therapeutics, Inc.       S-8         3/14/24    4:83K                                    Donnelley … Solutions/FA
 3/14/24  Allogene Therapeutics, Inc.       S-3                    8:1.1M                                   Donnelley … Solutions/FA
 3/14/24  Allogene Therapeutics, Inc.       POSASR      3/14/24    4:555K                                   Donnelley … Solutions/FA
 2/29/24  SEC                               UPLOAD3/28/24    2:39K  Allogene Therapeutics, Inc.
12/28/23  SEC                               UPLOAD3/28/24    2:50K  Allogene Therapeutics, Inc.
11/21/23  SEC                               UPLOAD3/28/24    2:48K  Allogene Therapeutics, Inc.
11/02/23  Allogene Therapeutics, Inc.       424B5                  2:542K                                   Donnelley … Solutions/FA
 2/28/23  Allogene Therapeutics, Inc.       S-8         2/28/23    4:130K


16 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/02/22  Allogene Therapeutics, Inc.       S-3ASR     11/02/22    9:1.7M
 8/09/22  Allogene Therapeutics, Inc.       10-Q        6/30/22   61:6.3M
 6/17/22  Allogene Therapeutics, Inc.       8-K:5,9     6/15/22   11:205K
 2/23/22  Allogene Therapeutics, Inc.       10-K       12/31/21   83:12M
 2/25/21  Allogene Therapeutics, Inc.       10-K       12/31/20   92:13M
 8/05/20  Allogene Therapeutics, Inc.       10-Q        6/30/20   63:7.3M
 5/06/20  Allogene Therapeutics, Inc.       10-Q        3/31/20   62:7.4M
 2/27/20  Allogene Therapeutics, Inc.       10-K       12/31/19   96:15M
11/05/19  Allogene Therapeutics, Inc.       10-Q        9/30/19   60:6.5M
 5/07/19  Allogene Therapeutics, Inc.       10-Q        3/31/19   55:6.4M                                   ActiveDisclosure/FA
 3/08/19  Allogene Therapeutics, Inc.       10-K       12/31/18   89:12M                                    ActiveDisclosure/FA
10/24/18  Allogene Therapeutics, Inc.       S-8        10/24/18    5:523K                                   Donnelley … Solutions/FA
10/15/18  Allogene Therapeutics, Inc.       8-K:5,8,9  10/15/18    4:168K                                   Donnelley … Solutions/FA
10/02/18  Allogene Therapeutics, Inc.       S-1/A                 15:6.4M                                   Donnelley … Solutions/FA
 9/17/18  Allogene Therapeutics, Inc.       S-1/A                  2:801K                                   Donnelley … Solutions/FA
 9/14/18  Allogene Therapeutics, Inc.       S-1                   14:7.5M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001737287-23-000018   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., May 11, 10:42:04.1am ET